Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 4.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 175,898 shares of the company’s stock after selling 9,126 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Mirum Pharmaceuticals were worth $16,249,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at about $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $32,000. CIBC Private Wealth Group LLC purchased a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth about $32,000. Quantbot Technologies LP purchased a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth about $33,000. Finally, Comerica Bank lifted its stake in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares in the last quarter.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 30,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at $18,622,574.56. This represents a 13.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $122.25, for a total value of $611,250.00. Following the sale, the chief financial officer owned 42,181 shares of the company’s stock, valued at $5,156,627.25. This represents a 10.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 65,315 shares of company stock worth $6,991,928 in the last quarter. 8.32% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Trading Down 5.9%

NASDAQ MIRM opened at $105.95 on Friday. The company’s fifty day simple moving average is $110.06 and its 200-day simple moving average is $101.40. Mirum Pharmaceuticals, Inc. has a 52 week low of $50.25 and a 52 week high of $130.00. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. The stock has a market cap of $6.46 billion, a P/E ratio of -7.78 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The firm had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. Mirum Pharmaceuticals’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.30) earnings per share. Equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MIRM. Citizens Jmp boosted their target price on Mirum Pharmaceuticals from $140.00 to $146.00 and gave the stock a “market outperform” rating in a report on Monday, June 15th. Stifel Nicolaus set a $136.00 price target on Mirum Pharmaceuticals in a report on Thursday, May 7th. CLSA set a $146.00 price objective on Mirum Pharmaceuticals in a research report on Monday, June 15th. Raymond James Financial reissued a “strong-buy” rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. boosted their price objective on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $143.40.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.